MESO-Rx Sponsor Pharmacom Labs officials and our Basicstero.com store

[Liter O' Test]

Basicstero gave me this video from Pharmacom Labs demonstrating the micronized Pharma STAN-50 suspension flowing through an insulin syringe.

View: https://www.youtube.com/watch?v=62whc_MKbGA

This is from the laboratory?

 

[RThoads]

This is from the laboratory?

I received the video from Basicstero and I assume Basicstero obtained it directly from Pharmacom Labs production or one of the warehouses.

 

[carbon adams]

Any takers?

No mention at all of the literature implicating EO as a key player in EtOH toxicity in humans. Neither good nor bad? Really?

I probably wouldn’t inject 1ml of eo straight into me.

I was thinking of trying their gso until I hear it has eo in it. Cause I don’t know either if it’s bad or good.

If they have 10% eo in their oils and I use their 300mg Sustanon.

That would mean I would inject 30mg of eo per 300mg of Sustanon ?



This what I found about if it safe or not.

“

Safety​

The absorption, distribution, and excretion of radiolabeled ethyl oleate (EO) was studied in Sprague–Dawley rats after a single, peroral dose of 1.7 or 3.4 g/kg body weight and was compared with a radiolabeled triacylglycerol (TG) containing only oleic acid as the fatty acid (triolein). Both test materials were well absorbed, with approximately 70–90% of the EO dose absorbed and approximately 90–100% of the TGdose absorbed[2]. At sacrifice (72 h post-dose), tissue distribution of EO-derived radioactivity and TG-derived radioactivity was similar. The tissue with the highest concentration of radioactivity in both groups was mesenteric fat. The other organs and tissues had very low concentrations of test material-derived radioactivity. Both test materials were rapidly and extensively excreted as CO2, with no remarkable differences between their excretion profiles. Approximately 40–70% of the administered dose for both groups was excreted as CO2 within the first 12 h (consistent with b-oxidation of fatty acids). Fecal elimination of EO appeared to be dose-dependent. At 1.7 g/kg, 7–8% of the administered dose was eliminated in the feces. At the dose of 3.4 g/kg, approximately 20% of the administered dose was excreted in the feces. Excretion of TG-derived radiolabel in the feces was approximately 2–4% for both doses. Overall, the results demonstrate that the absorption, distribution, and excretion of radiolabeled EO is similar to that of TG, providing evidence that the oleic acid moiety of EO is utilized in the body as a normal dietary TG-derived fatty acid.

To confirm the expected safety of EO in humans, a total of 235 subjects participated in a 12-week trial where two levels of ethyl oleate in a milk-based beverage were investigated: 8 g/day in a single serving (approximately 0.1 g/kg) and 16 g/day taken in two divided servings (approximately 0.2 g/kg). Adverse events (AEs) were recorded throughout the 12-week trial. In addition, a brief physical exam (including vital signs and body weight), ECGs, fasting serum chemistry profile, serum lipid profile, and urinalysis were performed at baseline and after study completion. Results showed that the incidence of reported AEs was similar between the EO and control groups. Analysis of comprehensive laboratory data revealed no EO exposure-related, clinically significant adverse changes in laboratory parameters. These studies demonstrated that EO has a highly favourable safety profile and is well tolerated in the diet.“